Patel Nikita, Al-Sayyed Ban, Gladfelter Taylor, Tripathi Sandeep
Medical student (NP), University of Illinois College of Medicine at Peoria, IL.
Department of Pediatrics (BAS), University of Illinois College of Medicine at Peoria, IL.
J Pediatr Pharmacol Ther. 2022;27(6):529-536. doi: 10.5863/1551-6776-27.6.529. Epub 2022 Aug 19.
Children with viral respiratory illness are often suspected of having bacterial coinfection. This study was designed to determine the impact of bacterial coinfection on hospital course and outcomes and the rate of antimicrobial misuse.
Single-center retrospective chart review, including all hospitalized children who had a respiratory viral panel sent within 48 hours of admission from January 2015 to December 2019. Patients who had a positive respiratory, urine, blood culture within 24 hours of admission were identified. Demographics, resource utilization, and outcomes were compared between the 2 groups.
This study included 2192 patients. Of those, 269 patients had positive bacterial cultures. Out of these cultures from 192 patients were identified as contaminants. True bacterial coinfection was 3.5% (77/2192). Almost 1/3 of admitted patients were prescribed empiric antimicrobials. Children with bacterial coinfection tended to be younger (median age 8.4 months vs 16.3 months, p < 0.01) and had higher proportion of prematurity (23.3% vs 12.1%, p < 0.01). Children with bacterial coinfection were more likely to require ICU admission (37.6% vs 23.9%, p < 0.01) and intubation (28.5% vs 5.3 %, p < 0.01). They had higher ICU (5.7 days vs 1.9 days, p < 0.01) and hospital length of stay (4.0 days vs 2.0 days, p < 0.01), higher mortality (2.6% vs 0.2%, p = 0.02), and a higher median cost of hospital care ($3774.44 vs $2424.49.90, p < 0.01).
The rate of bacterial coinfection in hospitalized children with viral infections is very low, which contradicts the routine administration of empiric antimicrobials. Patients with coinfection require more hospital resources and have worse clinical outcomes.
患有病毒性呼吸道疾病的儿童常被怀疑有细菌合并感染。本研究旨在确定细菌合并感染对住院病程及预后的影响以及抗菌药物滥用率。
单中心回顾性病历审查,纳入2015年1月至2019年12月入院48小时内进行呼吸道病毒检测的所有住院儿童。确定入院24小时内呼吸道、尿液、血培养呈阳性的患者。比较两组患者的人口统计学特征、资源利用情况及预后。
本研究纳入2192例患者。其中,269例患者细菌培养呈阳性。在这些培养结果中,192例被确定为污染菌。真正的细菌合并感染率为3.5%(77/2192)。近1/3的入院患者接受了经验性抗菌药物治疗。合并细菌感染的儿童往往年龄更小(中位年龄8.4个月对16.3个月,p<0.01),早产比例更高(23.3%对12.1%,p<0.01)。合并细菌感染的儿童更有可能需要入住重症监护病房(37.6%对23.9%,p<0.01)和进行插管(28.5%对5.3%,p<0.01)。他们的重症监护病房住院时间更长(5.7天对1.9天,p<0.01),住院时间更长(4.0天对2.0天,p<0.01),死亡率更高(2.6%对0.2%,p = 0.02),住院护理费用中位数更高(3774.44美元对242,449.90美元,p<0.01)。
住院病毒感染儿童的细菌合并感染率非常低,这与经验性使用抗菌药物的常规做法相矛盾。合并感染的患者需要更多的医院资源,临床预后更差。